Efficacy of pegylated interferon-α2a monotherapy in Japanese children with chronic hepatitis C

Hepatology Research

Volumn 41, Issue 5, 2011, Pages 399-404

  Tsunoda, Tomoyuki ^a   Inui, Ayano ^a   Etani, Yuri ^b   Kiyohara, Yuki ^c   Sugiura, Tokio ^d   Ito, Koichi ^d   Miyazawa, Reiko ^e   Nagata, Ikuo ^f   Ida, Shinobu ^b   Fujisawa, Tomoo ^a  

^a Yokohama Eastern Hospital   (Japan)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^e GUNMA UNIVERSITY   (Japan)

^f TOTTORI UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; Monotherapy; Pediatric; Pegylated interferon 2a

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; VIRUS RNA;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FLAVIVIRIDAE INFECTION; GASTROINTESTINAL DISEASE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; INFLUENZA; INJECTION SITE REACTION; JAPAN; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RETINOPATHY; SCHOOL CHILD; STOMATITIS;

EID: 79955148913     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00789.x     Document Type: Article

References (27)

1. Wong W, Terrault N. Update on chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3: 507-20.
2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin therapy for chronic hepatitis C. N Engl J Med 2006; 355: 2444-51.
3. National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36 (Suppl 1): S3-20.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
5. Dienstag JL, McHutchinson JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
6. Wirth S, Pieoer-Boustani H, Lang T etal. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-8.
7. Tajiri H, Inui A, Kiyohara Y etal. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. Eur J Gastroenterol Hepatol 2009; 21: 1256-60.
8. Jara P, Hierro L, de la Vega A etal. Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27: 142-8.
9. Baker RD, Dee D, Baker SS. Response to pegylated interferon α-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol 2007; 41: 111-4.
10. Schwarz KB, Parvathi M, Narkewicz MR etal. Safety and Pharmacokinetics of peginterferon α2a (40kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006; 43: 499-505.
11. Bedossa P, Poynard T. The French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
12. Sugiura T, Yamada T, Kimpara Y, Fujita N, Goto K, Koyama N. Effects of pegylated interferon α-2a on hepatitis-C-virus-associated glomerulonephritis. Pediatr Nephrol 2009; 24: 199-202.
13. Freid MW, Shiffman ML, Reddy KR etal. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
14. Davis GL, Wong JB, McHutchion JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
15. Ferenci P, Fried MW, Shiffman ML etal. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425-33.
16. Lindsay KL, Trepo C, Heintges T etal. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
17. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
18. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
19. Tajiri H, Inui A, Kiyohara Y etal. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. Eur J Gastroenterol Hepatol 2009; 21: 1256-60.
20. Kage M, Fujisawa T, Shiraki K etal. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology 1997; 26: 771-5.
21. Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 2008; 23: 226-30.
22. Alisi A, Comparcola D, Nobili V. Treatment of chronic hepatitis C in children: is it necessary and, if so, in whom? J Hepatol 2010; 52: 472-4.
23. Zeuzem S, Feinman SV, Rasenack J etal. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
24. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 52-8.
25. Komatsu H, Fujisawa T, Inui A etal. Efficacy of interferon in treating chronic hepatitis C in children with a history of acute leukemia. Blood 1996; 87: 4072-5.
26. Palumbo E. Treatment for chronic hepatitis C in children: a review. Am J Therapeut 2009; 16: 446-50.
27. Schwarz KB, Gonzalez-Peralta RP, Murray KF etal. Peginterferon with or without ribavirin for chronic hepatitis in children and adolescents: final results of the PEDS-C trial. Hepatology 2008; 48 (Suppl 1): A418.